Eloralintide

Eloralintide is designed as a receptor-selective amylin agonist - it targets AMY receptor complexes preferentially rather than binding the calcitonin receptor with equal affinity as cagrilintide does. The rationale is that some of the nausea and gastrointestinal burden of amylin analogues comes from calcitonin receptor activation, so selectivity should decouple satiety from sickness. The phase 2 results support that hypothesis: weight loss in the region of 20% at 48 weeks with no clear plateau, and tolerability far better than any incretin at comparable efficacy. It remains phase 2 data from a single programme, with no published long-term safety.

Targets: Amylin receptors (AMY1-3)

• · Phase 2 tested a range of escalating once-weekly doses over 48 weeks, with the highest arm reaching about 20.1% mean weight loss. The full dose-arm details have not been published in a peer-reviewed paper, so specific milligram figures are deliberately omitted here.

Work out your exact syringe units →

• commonNausea— Substantially lower rates than GLP-1 agonists at comparable weight loss.
• uncommonVomiting
• uncommonInjection-site reaction

• Pregnancy.
• Long-term human safety is unestablished - this is phase 2 material with no registration file behind it.

• synergytirzepatide — Lilly is developing eloralintide in combination with tirzepatide; separate receptors, additive effect.
• redundantcagrilintide — Both target the amylin axis.

• · Weight and body composition.
• · Protein intake.
• · Standard metabolic panel.

Investigational; not approved anywhere and not legitimately available.

• Eli Lilly 2025-2026, eloralintide phase 2 obesity results (trial)

Eloralintide is the strongest current test of the hypothesis that amylin selectivity buys tolerability without costing efficacy, and the phase 2 result is the most striking single dataset in the amylin field: roughly 20% mean weight loss at 48 weeks, which is tirzepatide territory, with a gastrointestinal profile reported as far cleaner than incretins produce. If that replicates in phase 3 it changes the shape of the field, because it means the nausea that has defined obesity pharmacotherapy for fifteen years was an artefact of which receptor was being hit rather than an unavoidable cost of appetite suppression. The mechanistic story is the same as petrelintide's - selective agonism at the calcitonin-receptor-plus-RAMP amylin complexes, with minimal engagement of the bare calcitonin receptor - executed by a different sponsor with apparently better results. The caveats are real and should be stated plainly. This is one phase 2 dataset from one sponsor, without an independent head-to-head, without long-term safety, and without any published mechanism for why eloralintide should be twice as effective as petrelintide when both are described as selective amylin agonists. Twenty percent from a mechanism that produced 10.8% (cagrilintide) and 10.7% (petrelintide) in comparable trials is a large enough discrepancy to warrant scepticism until phase 3 reads out.

There is no legitimate supply, so the practical failure is buying something labelled eloralintide from a research chemical vendor and receiving cagrilintide, or a peptide of no identity at all. The scientific caution is that a single phase 2 dataset reporting 20% from a mechanism that produced half that in two comparable programmes is a result to hold loosely until it replicates.

• Amylin receptors (AMY1R, AMY2R, AMY3R) — Not verified; characterised in the literature as selective for amylin receptors

  Area postrema satiation, slowed gastric emptying and postprandial glucagon suppression, with weekly duration and reportedly minimal nausea.

• Calcitonin receptor (CTR) — Reported as minimal - this is the design point

  Low engagement, which is the proposed explanation for the tolerability profile.

• Eloralintide phase 2 Phase 2 · 48 weeks · 2025

  Mean weight reduction reported at approximately 20% at the top dose over 48 weeks, with tolerability substantially better than incretin comparators.

• Eloralintide phase 1 proof of concept Phase 1 · 2026

  Safety, tolerability and initial weight-loss signal for a selective long-acting amylin receptor agonist.

Weight loss was still accruing at 48 weeks in phase 2. Onset and steady-state timing are not published in verified form.

Lilly's stated intent is to develop eloralintide both alone and combined with tirzepatide, which is the mechanistically obvious pairing and the one thing that could plausibly push weight loss past 30% with tolerable side effects. No combination data has been published. Outside a trial there is no supply, so any stacking discussion is hypothetical.

Against petrelintide and cagrilintide: roughly double the reported weight loss from the same nominal mechanism, which is either a genuinely better molecule or a result that will regress. Against tirzepatide: comparable reported efficacy with substantially better tolerability, which would be a very significant improvement if it survives phase 3. Against semaglutide: better on both axes in cross-trial comparison, which is the weakest form of comparison available. The correct posture is interest, not conviction.

Investigational; no legitimate supply and no price.

• ?No verified pharmacokinetic parameters.
• ?Participant numbers and exact dose levels for the phase 2 trial were not extracted in this session.
• ?The reason eloralintide would be roughly twice as effective as other selective amylin agonists is not explained anywhere and may not survive replication.
• ?No long-term safety data of any kind.
• ?Sequence and structure are not published in verifiable detail.

• Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial Billings LK et al., Lancet, 2025 · PMID 41207310

  The phase 2 result that made eloralintide the most interesting amylin compound in development.

• Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept Bhattachar S et al., Diabetes Obes Metab, 2026 · PMID 41559929

  First-in-human pharmacology.

• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept Briere DA et al., Mol Metab, 2025 · PMID 41109426

  The discovery and preclinical package, including the selectivity rationale.